Drug intelligence / Profile preview

ganyanshu decoction

Development stage: Preclinical
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

Ganyanshu decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Longhua Hospital of the Shanghai University of Traditional Chinese Medicine. It is specifically designed for the postoperative management of patients with hepatocellular carcinoma (HCC) to reduce the risk of tumor recurrence and metastasis. Like many TCM decoctions, it is a complex mixture of bioactive compounds that likely exert therapeutic effects through multiple pathways, including inhibition of tumor cell proliferation and enhancement of the host immune response. It is currently being evaluated in clinical trials in China for its efficacy and safety in preventing HCC recurrence after surgical resection.

Other names: Ganyanshu Decoctions

Beyond the preview

Go deeper on ganyanshu decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ganyanshu decoction.

Explore the full profile